$AWHL
CIPHERGEN BIOSYSTEMS INC
CIK:0000926617|SEC Filings
Condensed Consolidated Statements of Operations - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Condensed Consolidated Statements of Operations | ||||
| Revenue | $ 2,046,000 | $ 2,404,000 | $ 4,013,000 | $ 4,683,000 |
| Cost of revenue | 915,000 | 870,000 | 1,811,000 | 1,589,000 |
| Gross profit | 1,131,000 | 1,534,000 | 2,202,000 | 3,094,000 |
| Operating expenses: | ||||
| Research and development | 692,000 | 704,000 | 1,918,000 | 1,677,000 |
| Sales and marketing | 567,000 | 679,000 | 1,110,000 | 1,765,000 |
| General and administrative | 1,707,000 | 1,961,000 | 3,212,000 | 4,702,000 |
| Total operating expenses | 2,966,000 | 3,344,000 | 6,240,000 | 8,144,000 |
| Loss from operations | (1,835,000) | (1,810,000) | (4,038,000) | (5,050,000) |
| Other (expense) income, net: | ||||
| Change in fair value of warrant liabilities | (485,000) | (624,000) | 2,625,000 | 297,000 |
| Change in fair value of convertible notes | 170,000 | |||
| Loss upon issuance of convertible notes carried at fair value | (1,198,000) | (1,198,000) | ||
| Interest expense, net | (227,000) | (13,000) | (458,000) | (27,000) |
| Other (expense) income, net | 127,000 | (219,000) | 127,000 | 1,289,000 |
| Total other (expense) income, net | (585,000) | (856,000) | 2,294,000 | 531,000 |
| Net loss | $ (2,420,000) | $ (2,666,000) | $ (1,744,000) | $ (4,519,000) |
| Net loss per share - basic (in dollars per share) | $ (0.05) | $ (0.07) | $ (0.04) | $ (0.16) |
| Net loss per share - diluted (in dollars per share) | $ (0.05) | $ (0.07) | $ (0.04) | $ (0.16) |
| Weighted average common shares used to compute basic net loss per common share (in shares) | 44,249,591 | 35,564,032 | 43,875,165 | 28,579,132 |
| Weighted average common shares used to compute diluted net loss per common share (in shares) | 44,249,591 | 35,564,032 | 43,875,165 | 28,579,132 |